References
- 1. Gardner HL, Fenger JM, London CA: Dogs as a model for cancer. Annu Rev Anim Biosci 2016, 4:199-222.
- 2. Owen LN.: A comparative study of canine and human breast cancer. Invest Cell Pathol 1979, 2(4): 257-275.
- 3. Jensen-Jarolim E, Fazekas J, Singer J, Hofstetter G, Oida K, Matsuda H, Tanaka A: Crosstalk of carcinoembryonic antigen and transforming growth factor-β via their receptors: comparing human and canine cancer. Cancer Immunol Immunother 2015, 64: 531-537.
- 4. Meuten DJ: Tumors in domestic animals. Oxford: Wiley-Blackwell, 2002.
- 5. Hahn KA, Richardson RC, Knapp DW.: Canine malignant mammary neoplasia: Biological behaviour, diagnosis and treatment alternatives. J Am Anim Hosp Assoc 1992, 28: 251-256.
- 6. Campos LC, Lavalle GE, Estrela-Lima A, Melgaço De Faria JC, Guimarães JE, Dutra ÁP, Ferreira E, de Sousa LP, Rabelo ÉML, Vieira da Costa AFD, Cassali GD: CA 15.3, CEA and LDH in dogs with malignant mammary tumors. J Vet Int Med 2012, 26: 1383-1388.
- 7. Misdorp W, Else RW, Hellman E, Lipscomb TP: Histological classification of of mammary tumors of the dog and cat. In: World Health Organization: International Histological Classification of Tumors of Domestic Animals. Armed Forces Institute of Pathology 1999, 7(2).
- 8. Manuali E, De Giuseppe A, Feliziani F, Forti K, Casciari C, Marchesi M, Pacifico E, Pawlowski KM, Majchrzak K, Król M: CA 15-3 cell lines and tissue expression in canine mammary cancer and the correlation between serum levels and tumour histological grade. BMC Vet Res 2012, 8:86.
- 9. Campos LC, Silva JO, Santos FS, Arajúo MR, Lavalle GE, Ferreira E, Cassali GD: Prognostic significance of tissue and serum HER2 and MUC1 in canine mammary cancer. J Vet Diagn Invest 2015, 27: 531-535.
- 10. Sikorska H, Shuster J, Gold P.: Clinical applications of carcinoembryonic antigen. Cancer Detect Prev 1988, 12: 321-355.
- 11. Ferreira E, Gobbi H, Saraiva BS, Cassali GD.: Columnal cell lesions of the canine mammary gland: pathological features and immunophenotypic analysis. BMC Cancer 2010, 10: 61.
- 12. Molina R, Filella X, Alicarte J, Zanon G, Pahisa J, Monuz M, Farrus B, Ballesta AM: Prospective evaluation of CEA and CA 15-3 in patients with locoregional breast cancer. Anticancer Res 2003, 23: 1035-1041.
- 13. Valencakova-Agyagosova A, Frischova Z, Sevcikova Z, Hajurka J, Lepej J, Szakallova I, Kredatusova G, Nagy V, Ledecky V: Determination of carcinoembryonic antigen and cancer antigen (CA 15-3) in bitches with tumours on mammary gland: preliminary report. Vet Comp Oncol 2014, 12: 205-214.
- 14. Owen LN.: Classification of tumors in domestic animals, Geneva, World Health Organization 1980.
- 15. Gilson SD, Stone EA.: Principles of oncologic surgery. Compend Contin Educ Vet 1990, 12(6): 827-835.
- 16. Lamerz R, Stieber P, Fatel-Moghadam A.: Serum marker combinations in human breast cancer (review). In Vivo 1993, 7: 607–614.
- 17. O´´Hanlon DM, Kerin MJ, Kent PJ, Skehill R, Maher D, Grimes H, Given HF: A prospective evaluation of CA 15 – 3 in Stage I carcinomas of the breast. J Am Coll Surg 1995, 180: 210–212.
- 18. Fu Y, Li H: Assessing clinical significance of serum CA 15-3 and carcinoembryonic antigen (CEA) levels in breast cancer patients: a meta analysis. Med Sci Monit 2016, 22: 3154-3162.
- 19. Gioia D, Blankenburg I, Nagel D, Heinemann V, Stieber P: Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3. Clin Chim Acta 2016, 461: 1-7.
- 20. Ramadan ES, Salem NY, Emam IA, Abdelkader NA, Farghali HA, Khattab MS: MicroRNA-21 expression, serum tumor markers, and immunohistochemistry in canine mammary tumors. Vet Res Commun 2022, 46 (2): 377-388.
- 21. Jain M, Ingole SD, Deshmukh RS, Bharucha SV, Nagvekar AS, Gaikwad RV, Kharde SD: CEA, CA 15-3, and miRNA expression as potential biomarkers in canine mammary tumors. Chromosome Res 2021, 29 (2): 175-188.
- 22. Fan Y, Ren X, Liu X, Shi D, Xu E, Wang S, Liu Y: Combined detection of CA15-3, CEA, and SF in serum and tissue of canine mammary gland tumor patients. Sci Rep 2021, 11 (1): 6651.
- 23. Strieber P: Möglicher Einsaty der Tumormarker in der Nachsorge. Der Bayer Int 1996, 16(1): 42–54.
- 24. Park BW, Oh JW, Kim JH, Park SH, Kim KS, Lee KS: Preoperative CA 15 – 3 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol 2008, 19: 675–681.
- 25. Porika M, Malotu N, Veldandi Uk, Yadala N, Abbagani S: Evaluation of Tumor Markers in Southern Indian Breast Cancer Patients. Asian Pac J Cancer Prev 2010, 11: 157–160.
- 26. Marchesi MC, Manuali E, Pacifico E, Ferri C, Romagnoli M, Mangili V, Fruganti G: Cancer antigen 15/3: possible diagnostic use in veterinary clinical oncology. Preliminary study. Vet Res Commun 2010, 34: 103-106.
- 27. Pinheiro BQ, De Magalhães FF, Alves FWDS, Silva ING, Faustino AMR, Da Silva LDM: CA 15-3, CRP, and LDH correlates with prognostic parameters in canine mammary neoplasms. Anim Reprod 2023, 20 (1).
- 28. Kaušitz J: Nádorové markery. In: Kaušitz J, Altaner Č, editors. Onkológia, Bratislava: VEDA eds., Slovenskej akadémie vied 2003, 119-124.